Background
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed in Russia by the Institute of Molecular Genetics as a stable analog of the immunomodulatory peptide tuftsin. It was subsequently found to have anxiolytic properties comparable to benzodiazepines but without the associated sedation, cognitive impairment, or dependence risk.
Selank is approved in Russia for generalized anxiety disorder, neurasthenia, and cognitive impairment. It has growing off-label use internationally as a nootropic and anxiolytic.
Methods
Double-blind, randomized, placebo-controlled trial at a Russian psychiatric outpatient clinic. 62 patients with DSM-IV generalized anxiety disorder. Selank 0.15% nasal drops (0.15 mg per dose, 2 doses daily) vs. placebo for 14 days.
Primary outcomes: Hamilton Anxiety Rating Scale (HAM-A), Clinical Global Impression (CGI) scale, cognitive battery (attention, memory).
Key Findings
| Outcome | Selank | Placebo | p-value |
|---|---|---|---|
| HAM-A score reduction | −38% | −20% | 0.01 |
| CGI improvement (“much improved”) | 61% | 28% | 0.003 |
| Sedation score | No change | — | — |
| Cognitive battery | Improved or neutral | — | — |
| Dependence/withdrawal | None observed | — | — |
Clinical Significance
Selank’s anxiolytic efficacy without sedation or dependence represents a potentially important clinical differentiation from benzodiazepines. The cognitive neutrality (or mild enhancement) is also notable — most anxiolytics produce cognitive dulling.
The HAM-A reduction (-38% vs. -20%) approaches the magnitude seen with SSRIs in 8-week trials, achieved in only 14 days — consistent with a mechanism distinct from serotonergic adaptation (likely via enkephalin/opioid peptide modulation and BDNF upregulation).
Limitations
- Small sample (62 patients)
- Short duration (14 days) — insufficient for remission data
- Single center, single country; all published in Russian-language literature with limited Western peer review
- Mechanism not fully elucidated
- Long-term safety not established in controlled trials